Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.
about
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitusBreast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment.Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats.Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.The pharmacological perturbation of brain zinc impairs BDNF-related signaling and the cognitive performances of young mice.
P2860
Q26774021-76EE3070-4B57-4386-9C1C-F5CA0A0296C0Q34007740-409ED64D-FA36-4A67-801B-680DCB78A0D9Q36078803-B54F1ED0-D3D4-43B5-98CD-10234A14EDD7Q37516654-872B3CB7-C870-45F5-A7D7-9772D75E7F2BQ38200704-337F6466-87DE-414E-B2DC-B150E6FD0A58Q38286444-6947901B-48F0-4F73-8FAD-9A5EBDD95289Q38668948-ED3C4288-E341-40E5-B0D9-6EDDFC43AB78Q38974881-18292A0C-2A26-4D55-A906-A2516054585FQ39022532-8813F77E-D072-4BF2-A013-02CE215A3026Q42125458-72451B36-8272-4168-A851-773E9AA23A18Q46734353-70000B29-8C0A-4CD1-AF2A-E7945C7754A9Q47110701-AADF9699-3CAC-429D-9704-5DC6C0B727E5Q47785459-70A6A1A9-D265-4D5E-BEE1-11212D2F9C7AQ55513493-9FD02B83-7528-4581-800A-366A70D61431
P2860
Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Exenatide promotes cognitive e ...... no effects in 3xTg-AD animals.
@en
type
label
Exenatide promotes cognitive e ...... no effects in 3xTg-AD animals.
@en
prefLabel
Exenatide promotes cognitive e ...... no effects in 3xTg-AD animals.
@en
P2093
P2860
P50
P356
P1476
Exenatide promotes cognitive e ...... no effects in 3xTg-AD animals
@en
P2093
D Ciavardelli
E Silvestri
L M T Canzoniero
P Chiappini
P2860
P356
10.1038/CDDIS.2013.139
P577
2013-05-02T00:00:00Z